Primary T‐cell‐based delivery platform for in vivo synthesis of engineered proteins

Abstract

Primary T cell has been transformed into a cell‐based delivery platform that synthesizes complex biologics at the disease site with spatiotemporal resolution. This broadly applicable technology can circumvent toxicities due to systemic administration of biologics that necessitates the use of high doses and may diffuse to the healthy tissues. Its clinical translation, however, has been impeded by manufacturing bottlenecks. In this work, a range of process parameters were investigated for increasing the production yield of the primary T cells engineered for delivery function. Compared to the common spinoculation‐based method, the transduction yield was enhanced ~2.5‐fold by restricting the transduction reaction volume for maximizing the lentivector‐to‐T‐cell contact. Cell density and cytokines used in the expansion process were adjusted to achieve >100‐fold expansion of the T‐cell‐based delivery platform in 14 days, and the function of these cells was validated in vivo using intraperitoneally implanted tumor cells. The primary T‐cell‐based delivery platform has human applications because it can be scaled and administrated to express a broad range of therapeutic proteins (e.g., cytokines, interferons, enzymes, agonists, and antagonists) at the disease site, obviating the need for systemic delivery of large doses of these proteins.